Paragon 28 Stock Fair Value Calculation – PARAGON 28 Reports Fourth Quarter FY2022 Earnings of USD -38.8 Million, a Decrease of 528.2% YoY.

Earnings Overview

On December 31, 2022, PARAGON 28 ($NYSE:FNA) reported their financial results for the fourth quarter of FY2022, showcasing total revenue of USD -38.8 million, a decrease of 528.2% year-over-year. Net income, however, increased 20.4% to USD 51.5 million compared to the same period in 2023.

Price History

This dismal performance was reflected in the stock prices with the stock opening at $17.6 and closing at $17.5, down by 1.4% from the previous closing price of 17.8. The decrease in earnings is indicative of the challenges that PARAGON 28 is currently facing. Analysts believe that this is due to a combination of escalating costs and poor performance in the core product lines of the company. Furthermore, the uncertainty around the macroeconomic environment has weighed on the company’s outlook, further impacting its profits.

In response to these news, investors have adopted a wait-and-see attitude with the stock seeing little to no trading activity. Despite this, analysts are adamant that PARAGON 28 has potential to recover from this position and are optimistic that it can turn its fortunes around in the coming quarters. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Paragon 28. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Paragon 28. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Paragon 28. More…

Key Ratios Snapshot

Some of the financial key ratios for Paragon 28 are shown below. More…

Analysis – Paragon 28 Stock Fair Value Calculation

At GoodWhale, we have conducted an analysis of PARAGON 28‘s fundamentals. Our proprietary Valuation Line has calculated the fair value of PARAGON 28 share to be around $17.0. At the current moment, PARAGON 28 stock is traded at $17.5, which is a fair price but slightly overvalued by 3.0%. Therefore, investors should keep this in mind when making their decision. More…

Peers

The company was founded in 2013 and is headquartered in San Diego, California. Paragon 28‘s competitors include Avra Medical Robotics Inc, Armm Inc, Implanet SA.

– Avra Medical Robotics Inc ($OTCPK:AVMR)

Avra Medical Robotics Inc is a medical technology company that focuses on the development and commercialization of robot-assisted surgery systems. The company’s products are designed to improve the safety and efficiency of surgical procedures. Avra Medical Robotics Inc has a market cap of 317.5k as of 2022, a Return on Equity of 231.87%. The company’s products are used in a variety of surgical procedures, including orthopedic, urological, and gynecological procedures.

– Armm Inc ($OTCPK:ARMM)

Implanet SA is a French company that designs, manufactures, and markets medical devices for orthopedic surgery. The company was founded in 2001 and has a market capitalization of 5.51 million as of 2022. The company’s return on equity is -114.56%.

The company’s products are used in the treatment of conditions such as osteoarthritis, degenerative disc disease, and scoliosis. The company’s products are sold in over 50 countries worldwide.

Summary

PARAGON 28 has seen a year-over-year increase in net income, even with a decline in total revenue for the fourth quarter of FY2022. Investors should note that the decrease of 528.2% in total revenue compared to the same period in 2023 is significant, but that net income still rose by 20.4%. A further evaluation of the company’s financials and business strategy is recommended before investing.